Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.CoMentis, a biopharmaceutical company, has appointed Terence Kelly as the senior vice president for discovery and preclinical development, effective immediately. At CoMentis, he has responsibility for the Oklahoma City Research group.
Subscribe to our email newsletter
Previously, Dr Kelly has served for Boehringer Ingelheim for nearly 20 years, most recently as vice president of Chemistry.
Boehringer Ingelheim, develops and manufactures biopharmaceuticals by offering the entire production technology chain at its biopharmaceutical facilities in Biberach (Germany) and in Vienna (Austria).
Since joining Boehringer Ingelheim in 1990, Dr Kelly contributed to multiple projects that reached advanced clinical trials in the areas of HIV/AIDS, psoriasis and rheumatoid arthritis.
At Boehringer Ingelheim, Dr Kelly was responsible for the chemistry department which included high throughput screening, computational chemistry, structural biology and medicinal chemistry.
Scott Harkonen, president and CEO of CoMentis, said: “Terry’s international pharmaceutical experience in early-stage drug development, along with his medicinal chemistry expertise, are invaluable assets to CoMentis at this time.”